Entrada Q2 net income $55M, positive Phase 1 data for DMD candidate ENTR-601-44

Entrada Therapeutics, Inc.

2024-Q2 EPS reported $2.23 revenue$153,814,000

Q2 net income of $55.0M vs net loss of $25.9M YoY; collaboration revenue $94.7M (up from $18.2M).
Completed $100M registered direct offering; cash & securities $469.7M as of June 30, 2024; runway into 2027.
Phase 1 trial of ENTR-601-44 showed dose-dependent plasma/muscle concentration and exon skipping; no serious adverse events.
Planning global Phase 2 trials for ENTR-601-44 and ENTR-601-45; regulatory filings expected Q4 2024; ENTR-601-50 filing planned 2025.
Vertex VX-670 DM1 trial enrolling; SAD portion expected to complete by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.